Sveriges mest populära poddar
Research To Practice | Oncology Videos
Hälsa och motionMedicin

Multiple Myeloma | Oncology Today with Dr Neil Love: Emerging Role of CELMoDs (Cereblon E3 Ligase Modulators) and Other Novel Approaches to Targeting Protein Degradation Pathways in Multiple Myeloma (Companion Faculty Lecture)

34 min•28 september 2023

Featuring a slide presentation and related discussion from Dr Paul G Richardson, including the following topics:

  • Biologic rationale for targeting protein degradation pathways as a therapeutic approach in multiple myeloma (MM); mechanism of action of CELMoDs (0:00)
  • Published efficacy and safety findings with iberdomide-containing combination regimens from the Phase I/II CC-220-MM-001 study (6:30)
  • Emerging data with mezigdomide/dexamethasone for relapsed/refractory MM (13:22)
  • Early results with and ongoing investigations of mezigdomide/dexamethasone in combination with a proteasome inhibitor (29:54)

CME information and select publications

Fler avsnitt av Research To Practice | Oncology Videos

Visa alla avsnitt av Research To Practice | Oncology Videos
Oral SERDs for Breast Cancer | Erica Mayer, MD, MPH, FASCO
•29 min
Oral SERDs for Breast Cancer | Aditya Bardia, MD, MPH
•28 min
EGFR-Mutant Non-Small Cell Lung Cancer — Year in Review Series on Relevant New Datasets and Advances
•57 min
EGFR-Mutant Non-Small Cell Lung Cancer | Suresh S Ramalingam, MD
•26 min
EGFR-Mutant Non-Small Cell Lung Cancer | Helena Yu, MD
•30 min
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancers — Microlearning Activity 3: Proceedings from a Session Held Adjunct to the 2026 ASCO GI Cancers Symposium
•17 min
Prostate Cancer — Year in Review Series on Relevant New Datasets and Advances
•58 min
Prostate Cancer | Scott T Tagawa, MD, MS
•25 min
Prostate Cancer | Andrew J Armstrong, MD, ScM
•24 min
Menin Inhibitors in Acute Myeloid Leukemia — Year in Review Series on Relevant New Datasets and Advances
•59 min

Research To Practice | Oncology Videos med Dr Neil Love finns tillgänglig på flera plattformar. Informationen på denna sida kommer från offentliga podd-flöden.